Review



anti phospho her2 erbb2  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc anti phospho her2 erbb2
    Anti Phospho Her2 Erbb2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 312 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/Phospho-HER2%2FErbB2+(Tyr1221%2F1222)+Rabbit+mAb/pmc13041752-3-0-3
    Average 96 stars, based on 312 article reviews
    anti phospho her2 erbb2 - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma
    Article Snippet: Anti-HER2/ErbB2 , Cell Signaling , 2165.

    Article Title: Tyrosine kinase targeting uncovers oncogenic pathway plasticity in Tasmanian devil transmissible cancers
    Article Snippet: Anti-HER2/ErbB2 , Cell Signaling Technology , 4290.

    Western Blot:

    Article Title: Ezrin defines TSC complex activation at endosomal compartments through EGFR–AKT signaling
    Article Snippet: Antibody , anti-GAPDH (mouse monoclonal) , Santa Cruz , SC-32233 , WB (1:1000). .. Antibody , anti-HER2/ErbB2 (rabbit monoclonal) , Cell Signaling , 2165 , WB (1:1000). .. Antibody , anti-HER3/ErbB3 (rabbit monoclonal) , Cell Signaling , 12708 , WB (1:1000).

    Data-independent acquisition:

    Article Title: Increased Meflin expression in cancer-associated fibroblasts restrains tumor cell proliferation and shapes vessel-rich stroma in triple-negative breast cancer.
    Article Snippet: .. 157 The primary antibodies used in this study were as follows: anti-HER2/ErbB2 (clone 158 29D8, #2165, 1:400, Cell Signaling Technology, Danvers, MA, USA), anti-ER (clone 1D5, 159 #M7047, 1:400, Dako / Agilent Technologies), rat monoclonal anti-mouse CD31 (clone SZ31, 160 #DIA-310, 1:100, Dianova / BIOZOL, Eching, Germany), anti-CD31 (clone JC/70A, 161 #M0823, 1:100, Dako / Agilent Technologies), rat monoclonal anti-mouse Ki67 (clone TEC-162 Jo urn al Pr e-p r o f 3, #M7249, 1:100, Dako / Agilent Technologies), anti-α-SMA (clone 1A4, #M0852, 1:2000, 163 Dako / Agilent Technologies), and anti-podoplanin (clone D2-40, #ab77854, 1:100, Abcam 164 Cambridge, UK). .. The anti-Meflin antibody that we developed was diluted 10,000 times with 165 Immuno Shot (Cosmo Bio, Tokyo, Japan) before use.

    Staining:

    Article Title: Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis.
    Article Snippet: TZ was visualized in sections using anti-human Alexa Fluor 546 secondary antibody (Invitrogen) diluted 1:300 in blocking buffer and incubated overnight at 4 ◦C. .. HER2 was stained on adjacent slices with anti-HER2/ ErbB2 (29D8, Cell Signaling Technology, Inc.) diluted 1:200 in blocking buffer and incubated overnight at 4 ◦C as a primary detection antibody, and goat anti-rabbit Alexa Fluor 546 as secondary antibody (Invitrogen, 1:300) for 2 h at RT. .. Nuclei were stained with DAPI (0.1 μg/mL for 15 min) and slides were mounted in ProLong Gold antifade reagent (Invitrogen).

    Blocking Assay:

    Article Title: Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis.
    Article Snippet: TZ was visualized in sections using anti-human Alexa Fluor 546 secondary antibody (Invitrogen) diluted 1:300 in blocking buffer and incubated overnight at 4 ◦C. .. HER2 was stained on adjacent slices with anti-HER2/ ErbB2 (29D8, Cell Signaling Technology, Inc.) diluted 1:200 in blocking buffer and incubated overnight at 4 ◦C as a primary detection antibody, and goat anti-rabbit Alexa Fluor 546 as secondary antibody (Invitrogen, 1:300) for 2 h at RT. .. Nuclei were stained with DAPI (0.1 μg/mL for 15 min) and slides were mounted in ProLong Gold antifade reagent (Invitrogen).

    Incubation:

    Article Title: Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis.
    Article Snippet: TZ was visualized in sections using anti-human Alexa Fluor 546 secondary antibody (Invitrogen) diluted 1:300 in blocking buffer and incubated overnight at 4 ◦C. .. HER2 was stained on adjacent slices with anti-HER2/ ErbB2 (29D8, Cell Signaling Technology, Inc.) diluted 1:200 in blocking buffer and incubated overnight at 4 ◦C as a primary detection antibody, and goat anti-rabbit Alexa Fluor 546 as secondary antibody (Invitrogen, 1:300) for 2 h at RT. .. Nuclei were stained with DAPI (0.1 μg/mL for 15 min) and slides were mounted in ProLong Gold antifade reagent (Invitrogen).

    Article Title: Targeting cholesterol impairs cell invasion of all breast cancer types.
    Article Snippet: .. Membranes were blocked for 2 h in Tris Buffered Saline Tween (TBST)-5% milk and then incubated overnight at 4 °C with anti-Cortactin (1:1000), anti-phosphoCortactin (Cell Signaling Technology #4569, 1:1000), anti-Estrogen Receptor α (Santa Cruz #sc-8002, 1:200), anti-Progesterone Receptor (Santa Cruz #sc-166169, 1:200), anti-HER2/ErbB2 (Cell Signaling Technology #2165, 1:1000), anti-E-cadherin (BD Biosciences #610181, 1:2500), anti-Akt (Cell Signaling Technology #9272, 1:1000), anti-phospho-Akt (Cell Signaling Technology #4060, 1:2000) or anti-GAPDH (Millipore #ABS16, 1:1000) primary antibodies, washed and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies, all diluted in TBST-5% milk. .. Immunoreactive bands were revealed using Super Signal Chemiluminescent Substrate (ThermoFisher Scientific) and images were acquired using Fusion Solo S (Vilber Lourmat, Collegien, France).

    Article Title: Targeting cholesterol impairs cell invasion of all breast cancer types
    Article Snippet: .. Membranes were blocked for 2 h in Tris Buffered Saline Tween (TBST)-5% milk and then incubated overnight at 4 °C with anti-Cortactin (1:1000), anti-phospho-Cortactin (Cell Signaling Technology #4569, 1:1000), anti-Estrogen Receptor α (Santa Cruz #sc-8002, 1:200), anti-Progesterone Receptor (Santa Cruz #sc-166169, 1:200), anti-HER2/ErbB2 (Cell Signaling Technology #2165, 1:1000), anti-E-cadherin (BD Biosciences #610181, 1:2500), anti-Akt (Cell Signaling Technology #9272, 1:1000), anti-phospho-Akt (Cell Signaling Technology #4060, 1:2000) or anti-GAPDH (Millipore #ABS16, 1:1000) primary antibodies, washed and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies, all diluted in TBST-5% milk. .. Immunoreactive bands were revealed using Super Signal Chemiluminescent Substrate (ThermoFisher Scientific) and images were acquired using Fusion Solo S (Vilber Lourmat, Collegien, France).

    Saline:

    Article Title: Targeting cholesterol impairs cell invasion of all breast cancer types.
    Article Snippet: .. Membranes were blocked for 2 h in Tris Buffered Saline Tween (TBST)-5% milk and then incubated overnight at 4 °C with anti-Cortactin (1:1000), anti-phosphoCortactin (Cell Signaling Technology #4569, 1:1000), anti-Estrogen Receptor α (Santa Cruz #sc-8002, 1:200), anti-Progesterone Receptor (Santa Cruz #sc-166169, 1:200), anti-HER2/ErbB2 (Cell Signaling Technology #2165, 1:1000), anti-E-cadherin (BD Biosciences #610181, 1:2500), anti-Akt (Cell Signaling Technology #9272, 1:1000), anti-phospho-Akt (Cell Signaling Technology #4060, 1:2000) or anti-GAPDH (Millipore #ABS16, 1:1000) primary antibodies, washed and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies, all diluted in TBST-5% milk. .. Immunoreactive bands were revealed using Super Signal Chemiluminescent Substrate (ThermoFisher Scientific) and images were acquired using Fusion Solo S (Vilber Lourmat, Collegien, France).

    Article Title: Targeting cholesterol impairs cell invasion of all breast cancer types
    Article Snippet: .. Membranes were blocked for 2 h in Tris Buffered Saline Tween (TBST)-5% milk and then incubated overnight at 4 °C with anti-Cortactin (1:1000), anti-phospho-Cortactin (Cell Signaling Technology #4569, 1:1000), anti-Estrogen Receptor α (Santa Cruz #sc-8002, 1:200), anti-Progesterone Receptor (Santa Cruz #sc-166169, 1:200), anti-HER2/ErbB2 (Cell Signaling Technology #2165, 1:1000), anti-E-cadherin (BD Biosciences #610181, 1:2500), anti-Akt (Cell Signaling Technology #9272, 1:1000), anti-phospho-Akt (Cell Signaling Technology #4060, 1:2000) or anti-GAPDH (Millipore #ABS16, 1:1000) primary antibodies, washed and then incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies, all diluted in TBST-5% milk. .. Immunoreactive bands were revealed using Super Signal Chemiluminescent Substrate (ThermoFisher Scientific) and images were acquired using Fusion Solo S (Vilber Lourmat, Collegien, France).

    Chromatin Immunoprecipitation:

    Article Title: Spatiotemporally resolved mapping of extracellular proteomes via in vivo-compatible TyroID
    Article Snippet: .. | reporting sum m ary April2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. anti-v5 (catalog no. 460705, lot no. 2675745, Thermo Fisher, monoclonal), anti-HA (catalog no. HT301, lot no. R21030, TransGen, monoclonal), anti-GLUT1 (catalog no. ab15309, lot no. GR3180507-1, abcam, polyclonal), anti-citrate synthetase (catalog no. BM5202, lot no. BST17305202, BOSTER, polyclonal), anti-Calnexin (catalog no. A15631, lot no. 3561846101, ABclonal), AlexaFluor-488 (catalog no. 33206ES60, lot no. WA5318040, Yeasen), AlexaFluor-568 (catalog no. 175470, lot no. 1011082-3, abcam), AlexaFluor-647 (catalog no. 35104ES60, lot no. WA7317010, Yeasen), anti-GAPDH (catalog no. HC301, lot no. R20823, TransGen), HRP-labeled Streptavidin (catalog no. A0305-1, Beyotime), CD71 Monoclonal antibody (catalog no. 65236-1-Ig, Proteintech), Galectin-1 Monoclonal antibody (catalog no. 60223-1-Ig, Proteintech), anti-FLAG (catalog no. 66008-4-Ig, Proteintech), anti-HER2/ErbB2 (catalog no. 2165S, Cell Signaling Technology), anti-FUS (catalog no. 68262-1-lg, Proteintech, monoclonal). ..

    Flow Cytometry:

    Article Title: Spatiotemporally resolved mapping of extracellular proteomes via in vivo-compatible TyroID
    Article Snippet: .. | reporting sum m ary April2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. anti-v5 (catalog no. 460705, lot no. 2675745, Thermo Fisher, monoclonal), anti-HA (catalog no. HT301, lot no. R21030, TransGen, monoclonal), anti-GLUT1 (catalog no. ab15309, lot no. GR3180507-1, abcam, polyclonal), anti-citrate synthetase (catalog no. BM5202, lot no. BST17305202, BOSTER, polyclonal), anti-Calnexin (catalog no. A15631, lot no. 3561846101, ABclonal), AlexaFluor-488 (catalog no. 33206ES60, lot no. WA5318040, Yeasen), AlexaFluor-568 (catalog no. 175470, lot no. 1011082-3, abcam), AlexaFluor-647 (catalog no. 35104ES60, lot no. WA7317010, Yeasen), anti-GAPDH (catalog no. HC301, lot no. R20823, TransGen), HRP-labeled Streptavidin (catalog no. A0305-1, Beyotime), CD71 Monoclonal antibody (catalog no. 65236-1-Ig, Proteintech), Galectin-1 Monoclonal antibody (catalog no. 60223-1-Ig, Proteintech), anti-FLAG (catalog no. 66008-4-Ig, Proteintech), anti-HER2/ErbB2 (catalog no. 2165S, Cell Signaling Technology), anti-FUS (catalog no. 68262-1-lg, Proteintech, monoclonal). ..

    Magnetic Resonance Imaging:

    Article Title: Spatiotemporally resolved mapping of extracellular proteomes via in vivo-compatible TyroID
    Article Snippet: .. | reporting sum m ary April2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. anti-v5 (catalog no. 460705, lot no. 2675745, Thermo Fisher, monoclonal), anti-HA (catalog no. HT301, lot no. R21030, TransGen, monoclonal), anti-GLUT1 (catalog no. ab15309, lot no. GR3180507-1, abcam, polyclonal), anti-citrate synthetase (catalog no. BM5202, lot no. BST17305202, BOSTER, polyclonal), anti-Calnexin (catalog no. A15631, lot no. 3561846101, ABclonal), AlexaFluor-488 (catalog no. 33206ES60, lot no. WA5318040, Yeasen), AlexaFluor-568 (catalog no. 175470, lot no. 1011082-3, abcam), AlexaFluor-647 (catalog no. 35104ES60, lot no. WA7317010, Yeasen), anti-GAPDH (catalog no. HC301, lot no. R20823, TransGen), HRP-labeled Streptavidin (catalog no. A0305-1, Beyotime), CD71 Monoclonal antibody (catalog no. 65236-1-Ig, Proteintech), Galectin-1 Monoclonal antibody (catalog no. 60223-1-Ig, Proteintech), anti-FLAG (catalog no. 66008-4-Ig, Proteintech), anti-HER2/ErbB2 (catalog no. 2165S, Cell Signaling Technology), anti-FUS (catalog no. 68262-1-lg, Proteintech, monoclonal). ..

    Biomarker Discovery:

    Article Title: Spatiotemporally resolved mapping of extracellular proteomes via in vivo-compatible TyroID
    Article Snippet: .. | reporting sum m ary April2023 Materials & experimental systems n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology and archaeology Animals and other organisms Clinical data Dual use research of concern Plants Methods n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging Antibodies Antibodies used Validation Eukaryotic cell lines Policy information about cell lines and Sex and Gender in Research Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other research organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research Laboratory animals Wild animals Reporting on sex Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript. anti-v5 (catalog no. 460705, lot no. 2675745, Thermo Fisher, monoclonal), anti-HA (catalog no. HT301, lot no. R21030, TransGen, monoclonal), anti-GLUT1 (catalog no. ab15309, lot no. GR3180507-1, abcam, polyclonal), anti-citrate synthetase (catalog no. BM5202, lot no. BST17305202, BOSTER, polyclonal), anti-Calnexin (catalog no. A15631, lot no. 3561846101, ABclonal), AlexaFluor-488 (catalog no. 33206ES60, lot no. WA5318040, Yeasen), AlexaFluor-568 (catalog no. 175470, lot no. 1011082-3, abcam), AlexaFluor-647 (catalog no. 35104ES60, lot no. WA7317010, Yeasen), anti-GAPDH (catalog no. HC301, lot no. R20823, TransGen), HRP-labeled Streptavidin (catalog no. A0305-1, Beyotime), CD71 Monoclonal antibody (catalog no. 65236-1-Ig, Proteintech), Galectin-1 Monoclonal antibody (catalog no. 60223-1-Ig, Proteintech), anti-FLAG (catalog no. 66008-4-Ig, Proteintech), anti-HER2/ErbB2 (catalog no. 2165S, Cell Signaling Technology), anti-FUS (catalog no. 68262-1-lg, Proteintech, monoclonal). ..



    Similar Products

    fab1129a  (R&D Systems)
    93
    R&D Systems fab1129a
    Fab1129a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/Human+ErbB2%2FHer2+APC-conjugated+Antibody/us12613244-530-25-23
    Average 93 stars, based on 1 article reviews
    fab1129a - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    her2  (OriGene)
    94
    OriGene her2
    Her2, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/Her2+(ERBB2)+Mouse+Monoclonal+Antibody/10__3892_slash_ol__2026__15627-61-33-55
    Average 94 stars, based on 1 article reviews
    her2 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    monoclonal antibody mouse anti human erbb2 her2 apc  (R&D Systems)
    93
    R&D Systems monoclonal antibody mouse anti human erbb2 her2 apc
    Monoclonal Antibody Mouse Anti Human Erbb2 Her2 Apc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/Human+ErbB2%2FHer2+APC-conjugated+Antibody/us12613244-530-17-23
    Average 93 stars, based on 1 article reviews
    monoclonal antibody mouse anti human erbb2 her2 apc - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    anti-erbb2 / her2 antibody  (Advisains)
    99
    Advisains anti-erbb2 / her2 antibody
    Anti Erbb2 / Her2 Antibody, supplied by Advisains, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/Anti-ErbB2+%2F+HER2+antibody/custom%40ab16901%4010%2E64898%2F2026%2E04%2E15%2E716193
    Average 99 stars, based on 1 article reviews
    anti-erbb2 / her2 antibody - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    anti phospho her2 erbb2  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti phospho her2 erbb2
    Anti Phospho Her2 Erbb2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/Phospho-HER2%2FErbB2+(Tyr1221%2F1222)+Rabbit+mAb/pmc13041752-3-0-3
    Average 96 stars, based on 1 article reviews
    anti phospho her2 erbb2 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    anti her2 erbb2  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc anti her2 erbb2
    Anti Her2 Erbb2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/HER2%2FErbB2+Rabbit+mAb/pmc13041752-4-0-2
    Average 96 stars, based on 1 article reviews
    anti her2 erbb2 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    rabbit anti her2 mab  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc rabbit anti her2 mab
    Rabbit Anti Her2 Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/HER2%2FErbB2+Rabbit+mAb/pm41922471-273-28-32
    Average 96 stars, based on 1 article reviews
    rabbit anti her2 mab - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    her2  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc her2
    EBA downregulates <t>HER2,</t> p95HER2, HER3 and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.
    Her2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/HER2%2FErbB2+Rabbit+mAb/pmc12871574-33-30-31
    Average 96 stars, based on 1 article reviews
    her2 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    her3  (Cell Signaling Technology Inc)
    96
    Cell Signaling Technology Inc her3
    EBA downregulates HER2, p95HER2, <t>HER3</t> and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.
    Her3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+her2+erbb2/HER2%2FErbB2+Rabbit+mAb/pmc12871574-33-38-39
    Average 96 stars, based on 1 article reviews
    her3 - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    EBA downregulates HER2, p95HER2, HER3 and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.

    Journal: International Journal of Molecular Medicine

    Article Title: Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer

    doi: 10.3892/ijmm.2026.5751

    Figure Lengend Snippet: EBA downregulates HER2, p95HER2, HER3 and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.

    Article Snippet: Primary antibodies were as follows: Ki-67 (cat. no. ab16667), CD31 (cat. no. ab28364), ALDH1A1 (Abcam; cat. no. ab52492), Bcl-2 (Abcam; cat. no. ab692) and CD44 (all Abcam; cat. no. ab254530); HER2 (Cell Signaling Technology, Inc.; cat. no. 2165), HER3 (Cell Signaling Technology, Inc.; cat. no. 12708), phosphorylated (p-)HER2 (Y1221/1222; Cell Signaling Technology, Inc.; cat. no. 2243), p-HER3 (Y1289; Cell Signaling Technology, Inc.; cat. no. 2842), Akt (Cell Signaling Technology, Inc.; cat. no. 9272), p-Akt (S473; Cell Signaling Technology, Inc.; cat. no. 4060), PARP (Cell Signaling Technology, Inc.; cat. no. 9542), cleaved PARP (Cell Signaling Technology, Inc.; cat. no. 5625), caspase-3 (Cell Signaling Technology, Inc.; cat. no. 7148), -7 (Cell Signaling Technology, Inc.; cat. no. 12827) and -8 (Cell Signaling Technology, Inc.; cat. no. 4790), cleaved caspase-3 (Cell Signaling Technology, Inc.; cat. no. 9664), -7 (Cell Signaling Technology, Inc.; cat. no. 8438) and -8 (Cell Signaling Technology, Inc.; cat. no. 9496), Bax (Cell Signaling Technology, Inc.; cat. no. 2772) and vimentin (Cell Signaling Technology, Inc.; cat. no. 5741); anti-intracellular domain (ICD) HER2 clone 4B5 (Ventana Medical Systems; cat. no. 790-4493) and GAPDH (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. MA5-15738).

    Techniques: Expressing, Western Blot, In Silico, Binding Assay, Centrifugation, Immunoprecipitation

    EBA impairs cancer stem cell-like properties. (A) BT474 and SKBR3 cells were treated with EBA for 48 h, and ALDH1 activity was assessed by flow cytometry using the Aldefluor assay. DEAB was used to define the baseline of Aldefluor-positive fluorescence. (B) BT474 cells (5x10 4 cells/ml) were plated in ultra-low attachment dishes and cultured in the presence or absence of EBA for 5 days. The number and volume of mammospheres were measured by microscopy. (C) Overall survival of patients with breast cancer stratified by the co-expression of ALDH1A1 and CD44. (D) Spearman correlation analysis of ALDH1A1 and CD44 mRNA levels in patients with HER2-positive breast cancer from The Cancer Genome Atlas cohort (n=76). Kaplan-Meier survival analyses of patients with HER2-overexpressing breast cancer stratified by (E) ALDH1A1 and (F) CD44 expression. Patients were divided into high- and low-expression groups based on the median gene expression. Statistical significance was determined using the log-rank test. (G) JIMT-1 cells were treated with EBA (3 μ M) for 48 h and the CD44 high /CD24 low cell populations were identified by flow cytometry. (H) JIMT-1 cells (1.5x10 4 cells/ml) were cultured under serum-free suspension conditions in the presence of EBA (3 μ M) for 8 days. Mammosphere number and volumes were quantified. ** P<0.01 and **** P<0.0001 vs. vehicle-treated control (0 μ M EBA). EBA, ebastine; ALDH, aldehyde dehydrogenase; DEAB, diethylaminobenzaldehyde; CTL, control; ISO, isotype.

    Journal: International Journal of Molecular Medicine

    Article Title: Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer

    doi: 10.3892/ijmm.2026.5751

    Figure Lengend Snippet: EBA impairs cancer stem cell-like properties. (A) BT474 and SKBR3 cells were treated with EBA for 48 h, and ALDH1 activity was assessed by flow cytometry using the Aldefluor assay. DEAB was used to define the baseline of Aldefluor-positive fluorescence. (B) BT474 cells (5x10 4 cells/ml) were plated in ultra-low attachment dishes and cultured in the presence or absence of EBA for 5 days. The number and volume of mammospheres were measured by microscopy. (C) Overall survival of patients with breast cancer stratified by the co-expression of ALDH1A1 and CD44. (D) Spearman correlation analysis of ALDH1A1 and CD44 mRNA levels in patients with HER2-positive breast cancer from The Cancer Genome Atlas cohort (n=76). Kaplan-Meier survival analyses of patients with HER2-overexpressing breast cancer stratified by (E) ALDH1A1 and (F) CD44 expression. Patients were divided into high- and low-expression groups based on the median gene expression. Statistical significance was determined using the log-rank test. (G) JIMT-1 cells were treated with EBA (3 μ M) for 48 h and the CD44 high /CD24 low cell populations were identified by flow cytometry. (H) JIMT-1 cells (1.5x10 4 cells/ml) were cultured under serum-free suspension conditions in the presence of EBA (3 μ M) for 8 days. Mammosphere number and volumes were quantified. ** P<0.01 and **** P<0.0001 vs. vehicle-treated control (0 μ M EBA). EBA, ebastine; ALDH, aldehyde dehydrogenase; DEAB, diethylaminobenzaldehyde; CTL, control; ISO, isotype.

    Article Snippet: Primary antibodies were as follows: Ki-67 (cat. no. ab16667), CD31 (cat. no. ab28364), ALDH1A1 (Abcam; cat. no. ab52492), Bcl-2 (Abcam; cat. no. ab692) and CD44 (all Abcam; cat. no. ab254530); HER2 (Cell Signaling Technology, Inc.; cat. no. 2165), HER3 (Cell Signaling Technology, Inc.; cat. no. 12708), phosphorylated (p-)HER2 (Y1221/1222; Cell Signaling Technology, Inc.; cat. no. 2243), p-HER3 (Y1289; Cell Signaling Technology, Inc.; cat. no. 2842), Akt (Cell Signaling Technology, Inc.; cat. no. 9272), p-Akt (S473; Cell Signaling Technology, Inc.; cat. no. 4060), PARP (Cell Signaling Technology, Inc.; cat. no. 9542), cleaved PARP (Cell Signaling Technology, Inc.; cat. no. 5625), caspase-3 (Cell Signaling Technology, Inc.; cat. no. 7148), -7 (Cell Signaling Technology, Inc.; cat. no. 12827) and -8 (Cell Signaling Technology, Inc.; cat. no. 4790), cleaved caspase-3 (Cell Signaling Technology, Inc.; cat. no. 9664), -7 (Cell Signaling Technology, Inc.; cat. no. 8438) and -8 (Cell Signaling Technology, Inc.; cat. no. 9496), Bax (Cell Signaling Technology, Inc.; cat. no. 2772) and vimentin (Cell Signaling Technology, Inc.; cat. no. 5741); anti-intracellular domain (ICD) HER2 clone 4B5 (Ventana Medical Systems; cat. no. 790-4493) and GAPDH (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. MA5-15738).

    Techniques: Activity Assay, Flow Cytometry, Fluorescence, Cell Culture, Microscopy, Expressing, Gene Expression, Suspension, Control

    EBA downregulates HER2, ICD-HER2, HER3, ALDH1A1, CD44 and vimentin in JIMT-1 xenograft tumors. Immunofluorescence staining of JIMT-1 xenograft tumor tissue for (A) full-length HER2 (green), (B) ICD-HER2 (green) and (C) HER3. Immunohistochemical analysis of (D) ALDH1A1 (green) and (E) CD44 (red) in tumor tissue. (F) Tumor sections were immunostained for vimentin (red). Magnification, x500. Fluorescence intensities were quantified. Serum biochemical analysis for (G) liver and (H) kidney function in EBA-treated or CTL mice (n=5). Serum levels of ALT, AST, TBL, BUN and creatinine were assessed. *** P<0.001, **** P<0.0001. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; EBA, ebastine; ICD, intracellular domain; ALDH, aldehyde dehydrogenase; CTL, control; NS, not significant.

    Journal: International Journal of Molecular Medicine

    Article Title: Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer

    doi: 10.3892/ijmm.2026.5751

    Figure Lengend Snippet: EBA downregulates HER2, ICD-HER2, HER3, ALDH1A1, CD44 and vimentin in JIMT-1 xenograft tumors. Immunofluorescence staining of JIMT-1 xenograft tumor tissue for (A) full-length HER2 (green), (B) ICD-HER2 (green) and (C) HER3. Immunohistochemical analysis of (D) ALDH1A1 (green) and (E) CD44 (red) in tumor tissue. (F) Tumor sections were immunostained for vimentin (red). Magnification, x500. Fluorescence intensities were quantified. Serum biochemical analysis for (G) liver and (H) kidney function in EBA-treated or CTL mice (n=5). Serum levels of ALT, AST, TBL, BUN and creatinine were assessed. *** P<0.001, **** P<0.0001. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; EBA, ebastine; ICD, intracellular domain; ALDH, aldehyde dehydrogenase; CTL, control; NS, not significant.

    Article Snippet: Primary antibodies were as follows: Ki-67 (cat. no. ab16667), CD31 (cat. no. ab28364), ALDH1A1 (Abcam; cat. no. ab52492), Bcl-2 (Abcam; cat. no. ab692) and CD44 (all Abcam; cat. no. ab254530); HER2 (Cell Signaling Technology, Inc.; cat. no. 2165), HER3 (Cell Signaling Technology, Inc.; cat. no. 12708), phosphorylated (p-)HER2 (Y1221/1222; Cell Signaling Technology, Inc.; cat. no. 2243), p-HER3 (Y1289; Cell Signaling Technology, Inc.; cat. no. 2842), Akt (Cell Signaling Technology, Inc.; cat. no. 9272), p-Akt (S473; Cell Signaling Technology, Inc.; cat. no. 4060), PARP (Cell Signaling Technology, Inc.; cat. no. 9542), cleaved PARP (Cell Signaling Technology, Inc.; cat. no. 5625), caspase-3 (Cell Signaling Technology, Inc.; cat. no. 7148), -7 (Cell Signaling Technology, Inc.; cat. no. 12827) and -8 (Cell Signaling Technology, Inc.; cat. no. 4790), cleaved caspase-3 (Cell Signaling Technology, Inc.; cat. no. 9664), -7 (Cell Signaling Technology, Inc.; cat. no. 8438) and -8 (Cell Signaling Technology, Inc.; cat. no. 9496), Bax (Cell Signaling Technology, Inc.; cat. no. 2772) and vimentin (Cell Signaling Technology, Inc.; cat. no. 5741); anti-intracellular domain (ICD) HER2 clone 4B5 (Ventana Medical Systems; cat. no. 790-4493) and GAPDH (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. MA5-15738).

    Techniques: Immunofluorescence, Staining, Immunohistochemical staining, Fluorescence, Control

    EBA downregulates HER2, p95HER2, HER3 and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.

    Journal: International Journal of Molecular Medicine

    Article Title: Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer

    doi: 10.3892/ijmm.2026.5751

    Figure Lengend Snippet: EBA downregulates HER2, p95HER2, HER3 and AKT expression. (A) Immunoblot analysis of HER2, p95HER2 and p-HER2 (Y1221/1222) in JIMT-1 cells treated with EBA for 48 h. (B) Immunoblot analysis of HER3, p-HER3 (Y1289), AKT and p-AKT following treatment with EBA (48 h) in JIMT-1 cells. (C) Immunoblot analysis of HER2, HER3 and EGFR following IP with anti-HER2 antibody in JIMT-1 cells treated with EBA. In silico molecular docking of EBA with the crystal structure of HER2-KD. (D) Surface map of lipophilic and hydrophilic properties at the ATP-binding site of HER2-KD (red, hydrophobic; blue, hydrophilic). (E) 2D interaction diagram showing intermolecular interactions between EBA and HER2-KD. Key amino acid residues within the binding pocket are shown. (F) Predicted binding pose of EBA (purple stick model) within the tyrosine kinase domain of HER2 (blue ribbon). (G) 293T cells were treated with DMSO or EBA for 1 h at 37°C, followed by heating for 3 min. Soluble fractions were collected following centrifugation and analyzed by immunoblotting using an anti-HER2 antibody. EBA, ebastine; p-, phosphorylated; IP, immunoprecipitation; IB, immunoblotting; KD, kinase domain PCB, protein complex binding; TM, transmembrane; a.a., amino acid.

    Article Snippet: Primary antibodies were as follows: Ki-67 (cat. no. ab16667), CD31 (cat. no. ab28364), ALDH1A1 (Abcam; cat. no. ab52492), Bcl-2 (Abcam; cat. no. ab692) and CD44 (all Abcam; cat. no. ab254530); HER2 (Cell Signaling Technology, Inc.; cat. no. 2165), HER3 (Cell Signaling Technology, Inc.; cat. no. 12708), phosphorylated (p-)HER2 (Y1221/1222; Cell Signaling Technology, Inc.; cat. no. 2243), p-HER3 (Y1289; Cell Signaling Technology, Inc.; cat. no. 2842), Akt (Cell Signaling Technology, Inc.; cat. no. 9272), p-Akt (S473; Cell Signaling Technology, Inc.; cat. no. 4060), PARP (Cell Signaling Technology, Inc.; cat. no. 9542), cleaved PARP (Cell Signaling Technology, Inc.; cat. no. 5625), caspase-3 (Cell Signaling Technology, Inc.; cat. no. 7148), -7 (Cell Signaling Technology, Inc.; cat. no. 12827) and -8 (Cell Signaling Technology, Inc.; cat. no. 4790), cleaved caspase-3 (Cell Signaling Technology, Inc.; cat. no. 9664), -7 (Cell Signaling Technology, Inc.; cat. no. 8438) and -8 (Cell Signaling Technology, Inc.; cat. no. 9496), Bax (Cell Signaling Technology, Inc.; cat. no. 2772) and vimentin (Cell Signaling Technology, Inc.; cat. no. 5741); anti-intracellular domain (ICD) HER2 clone 4B5 (Ventana Medical Systems; cat. no. 790-4493) and GAPDH (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. MA5-15738).

    Techniques: Expressing, Western Blot, In Silico, Binding Assay, Centrifugation, Immunoprecipitation

    EBA downregulates HER2, ICD-HER2, HER3, ALDH1A1, CD44 and vimentin in JIMT-1 xenograft tumors. Immunofluorescence staining of JIMT-1 xenograft tumor tissue for (A) full-length HER2 (green), (B) ICD-HER2 (green) and (C) HER3. Immunohistochemical analysis of (D) ALDH1A1 (green) and (E) CD44 (red) in tumor tissue. (F) Tumor sections were immunostained for vimentin (red). Magnification, x500. Fluorescence intensities were quantified. Serum biochemical analysis for (G) liver and (H) kidney function in EBA-treated or CTL mice (n=5). Serum levels of ALT, AST, TBL, BUN and creatinine were assessed. *** P<0.001, **** P<0.0001. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; EBA, ebastine; ICD, intracellular domain; ALDH, aldehyde dehydrogenase; CTL, control; NS, not significant.

    Journal: International Journal of Molecular Medicine

    Article Title: Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2-positive breast cancer

    doi: 10.3892/ijmm.2026.5751

    Figure Lengend Snippet: EBA downregulates HER2, ICD-HER2, HER3, ALDH1A1, CD44 and vimentin in JIMT-1 xenograft tumors. Immunofluorescence staining of JIMT-1 xenograft tumor tissue for (A) full-length HER2 (green), (B) ICD-HER2 (green) and (C) HER3. Immunohistochemical analysis of (D) ALDH1A1 (green) and (E) CD44 (red) in tumor tissue. (F) Tumor sections were immunostained for vimentin (red). Magnification, x500. Fluorescence intensities were quantified. Serum biochemical analysis for (G) liver and (H) kidney function in EBA-treated or CTL mice (n=5). Serum levels of ALT, AST, TBL, BUN and creatinine were assessed. *** P<0.001, **** P<0.0001. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; EBA, ebastine; ICD, intracellular domain; ALDH, aldehyde dehydrogenase; CTL, control; NS, not significant.

    Article Snippet: Primary antibodies were as follows: Ki-67 (cat. no. ab16667), CD31 (cat. no. ab28364), ALDH1A1 (Abcam; cat. no. ab52492), Bcl-2 (Abcam; cat. no. ab692) and CD44 (all Abcam; cat. no. ab254530); HER2 (Cell Signaling Technology, Inc.; cat. no. 2165), HER3 (Cell Signaling Technology, Inc.; cat. no. 12708), phosphorylated (p-)HER2 (Y1221/1222; Cell Signaling Technology, Inc.; cat. no. 2243), p-HER3 (Y1289; Cell Signaling Technology, Inc.; cat. no. 2842), Akt (Cell Signaling Technology, Inc.; cat. no. 9272), p-Akt (S473; Cell Signaling Technology, Inc.; cat. no. 4060), PARP (Cell Signaling Technology, Inc.; cat. no. 9542), cleaved PARP (Cell Signaling Technology, Inc.; cat. no. 5625), caspase-3 (Cell Signaling Technology, Inc.; cat. no. 7148), -7 (Cell Signaling Technology, Inc.; cat. no. 12827) and -8 (Cell Signaling Technology, Inc.; cat. no. 4790), cleaved caspase-3 (Cell Signaling Technology, Inc.; cat. no. 9664), -7 (Cell Signaling Technology, Inc.; cat. no. 8438) and -8 (Cell Signaling Technology, Inc.; cat. no. 9496), Bax (Cell Signaling Technology, Inc.; cat. no. 2772) and vimentin (Cell Signaling Technology, Inc.; cat. no. 5741); anti-intracellular domain (ICD) HER2 clone 4B5 (Ventana Medical Systems; cat. no. 790-4493) and GAPDH (Invitrogen; Thermo Fisher Scientific, Inc.; cat. no. MA5-15738).

    Techniques: Immunofluorescence, Staining, Immunohistochemical staining, Fluorescence, Control